Source: Annual Congress 2005 - Novel therapies for asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Duvauchelle, B. Elharrar, H. Knight, A. Krebbs-Brown, S. Perry, P. Freeman, L. Brookman (Paris, France; Basel, Switzerland; Horsham, United Kingdom). Single-dose indacaterol, a novel 24-hour β₂-agonist, is well tolerated in patients with mild asthma. Eur Respir J 2005; 26: Suppl. 49, 1727

Member's Comments

No comment yet.

Related content which might interest you: Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2-agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Indacaterol, a novel 24-hour β2-agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005 Safety of multiple-dose indacaterol, a novel 24-hour β2-agonist, in moderate to severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Indacaterol, a novel once-daily β2-agonist, is well tolerated in persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 204s Year: 2006 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Indacaterol, a novel once-daily β2-agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Indacaterol, a novel β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006 Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD, and comparison with formoterol Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Source: Eur Respir J 2011; 37: 273 Year: 2011 Cardiovascular safety of indacaterol, a novel 24-hour β2-agonist, in patients with stable asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Cardiovascular safety of qva149, a novel combination of indacaterol and glycopyrronium, compared with indacaterol and placebo in patients with COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009 Cardiac safety of indacaterol, a novel once-daily bronchodilator, in asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012 NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Qva149, a novel combination of indacaterol and glycopyrronium, demonstrates superior bronchodilation compared with indacaterol or placebo in patients with COPD Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009